Navigation Links
Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients
Date:2/27/2009

American Journal of Surgery Study Reveals Conclusive Findings

NEWPORT NEWS, Va., Feb. 27 /PRNewswire/ -- Women facing a recent breast cancer diagnosis may find additional cancer in the same or opposite breast with further testing using Breast-Specific Gamma Imaging (BSGI) according to a study published in the February 2009 "American Journal of Surgery." BSGI detected additional or more extensive breast cancer in the same or opposite breast in 10.9 percent of newly diagnosed patients according to the study.

BSGI, a molecular breast imaging technique, is a follow-up to mammography that can see lesions independent of tissue density and discover early stage cancers. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image. The Dilon 6800 Gamma Camera is a high-resolution, compact field-of-view gamma camera, optimized to perform BSGI.

"The research is important because it helps clarify the role of BSGI in newly diagnosed breast cancer patients. We have found that these women can have more extensive disease that is not detected by mammography or ultrasonography. This is especially helpful in patients with dense breast tissue where additional evaluation of the remaining breast tissue is necessary," said Nathalie Johnson, M.D., general surgeon and surgical oncologist at Good Samaritan Hospital, Portland, Ore.

Johnson and her team conducted a retrospective review from two Portland, Ore. community-based breast imaging centers of newly diagnosed breast cancer patients in whom BSGI was performed as part of the imaging work-up. BSGI detected additional or more extensive malignancy in the same or opposite breast in 10.9 percent of newly diagnosed breast cancer patients. Only 7.2 percent incurred an additional work-up. The study concluded that BSGI provides accurate evaluation of remaining breast tissue in newly diagnosed breast cancer patients with few false-positive readings.

BSGI has comparable sensitivity, but superior specificity when compared to magnetic resonance imaging (MRI), which leads to improved management of the newly diagnosed breast cancer patient. Sensitivity refers to the ability of an imaging technique to detect the presence of disease. Specificity refers to the technique's ability to detect that disease is actually not present.

"The biggest benefit of BSGI is the specificity. The sensitivity of BSGI is on par with MRI, but the specificity is higher than MRI. In addition, when compared to MRI, BSGI is less expensive and easier to use for patient and physician," said Johnson.

Study Results

A total of 138 patients (69 invasive ductal carcinoma, 20 invasive lobular carcinoma, 32 ductal carcinoma in situ, and 17 mixtures of invasive ductal carcinoma, invasive lobular carcinoma, or ductal carcinoma in situ and other) were reviewed. Twenty-five patients (18.1%) had a positive BSGI study for cancer at a site other than their known cancer, or more extensive disease than was detected from previous imaging. Fifteen patients (10.9%) were positive for a synchronous or more extensive cancer in the same or opposite breast. Five patients had benign findings on pathology, five benign on ultrasound follow-up (false-positive rate, 7.2%). Findings converted seven patients to mastectomy, one patient to neoadjuvant chemotherapy, and seven patients were found to have previously undetected contralateral cancer. The positive predictive value for BSGI was 92.9%.

The full study can be found in The American Journal of Surgery, Vol 197, No 2, February 2009.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit www.dilon.com.


'/>"/>
SOURCE Dilon Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dilon Technologies Signs Amerinet for Breast-Specific Gamma Imaging
2. Breast-Specific Gamma Imaging (BSGI) Found to Be Highly Sensitive for Early Stage Breast Cancer
3. Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
4. Breast-Specific Gamma Imaging (BSGI) Changes Patient Care Management
5. Study Determines Breast-Specific Gamma Imaging Has Higher Specificity Than MRI in Patients With Equivocal Mammograms
6. M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments
7. ETEX Corporation Announces CE Mark of Beta-bsm and Gamma-bsm
8. What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
9. Dual-head gamma camera increases ability to detect breast tumors not seen on mammography
10. Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
11. STERIS Isomedix Services Offers Gamma Engineering Run Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... health plan partners, announced during the 2017 Annual HIMSS Conference & Exhibition ... for diabetic patients and integrating eye care into mainstream healthcare delivery is ...
(Date:2/19/2017)... ... February 19, 2017 , ... Braun Industries will be participating as ... the event will take place February 23-25, 2017 at the Calvin L. Rampton Salt ... #909 with three new ambulances on display. , “JEMS is a ...
(Date:2/19/2017)... , ... February 19, 2017 , ... ... for connected home healthcare, will join forces with Healthwise ® at ... Healthwise, the industry leader in evidence-based health education, technology and services, will ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews to ... other Butler products. Ken was impressed with the safety and reliability of the ... product on his show. This endorsement by Ken Matthews can be heard on ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line ... other applications. Users can pick and choose from hand-crafted trend-setting designs with ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017 Theravance Biopharma, ... or the "Company") today announced the presentation of ... and orally administered pan-Janus kinase (JAK) inhibitor designed ... Congress of the European Crohn,s and Colitis ... reported further data from its completed Phase 1 ...
(Date:2/17/2017)... Research and Markets has announced the addition of ... their offering. ... separate comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ... Also, a six-year historic analysis is provided for these markets. Market data ...
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , ... announced a new partnership with Engage , one ... United States . FormFast will serve as the ... Engage,s implementations with MEDITECH .  ... essential functionality to complement and enhance the electronic health ...
Breaking Medicine Technology: